Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Updates On Cymbalta, Zyprexa, Cialis Expected At Dec. 9 Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Cymbalta was launched for depression in August; Lilly anticipates first half 2005 approval of duloxetine for stress urinary incontinence under the Yentreve name. Patent challenges to the antipsychotic Zyprexa and Lilly’s cost-cutting efforts are also likely topics at the investor meeting.

You may also be interested in...



Zyprexa Court Prepares For Ruling In Patent Case

Indianapolis court plans special procedures for announcing its bench verdict on infringement and invalidity claims involving Zyprexa. Lilly and ANDA filers Ivax, Dr. Reddy’s and Teva are admonished “not to speculate about the timing of the opinion.”

Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta

FDA’s neuropharm and urology review divisions hold differing opinions on duloxetine drug interactions, Cymbalta review documents indicate. Due to potential QT risk, urology division delays Yentreve approval for stress urinary incontinence; neuropharm division believes potential QT effect can be considered post-approval.

Lilly Cost-Cutting Program Will Eliminate 1,000 Positions

The restructuring program will affect R&D, manufacturing and sales & marketing. The program is expected to be completed by Mach 31, 2005, and will result in net savings of $150 mil. for 2005. Lilly’s third quarter sales rose 4% to $3.28 bil.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel